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BACKGROUND: Obesity is associated with insulin resistance, hypertension, and cardiovascular disease, but the mechanisms underlying these 
associations are incompletely understood. Microvascular 
dysfunction may play an important role in the pathogenesis 
of both insulin resistance and hypertension in obesity.
CONTENT: Perivascular adipose tissue (PVAT) is a local 
deposit of adipose tissue surrounding the vasculature. PVAT 
is present throughout the body and has been shown to have 
a local effect on blood vessels. The influence of PVAT on 
the vasculature changes with increasing adiposity. PVAT 
similarly to other fat depots, is metabolically active, secreting 
a wide array of bioactive substances, termed ‘adipokines’. 
Adipokines include cytokines, chemokines and hormones 
that can act in a paracrine, autocrine or endocrine fashion. 
Many of the proinflammatory adipokines upregulated in 
obesity are known to influence vascular function, including 
endothelial function, oxidative stress, vascular stiffness 
and smooth muscle migration. Adipokines also stimulate 
immune cell migration into the vascular wall, potentially 
contributing to the inflammation found in atherosclerosis. 
Finally, adipokines modulate the effect of insulin on the 
vasculature, thereby decreasing insulin-mediated muscle 
glucose uptake. This leads to alterations in nitric oxide 
signaling, insulin resistance and potentially atherogenesis.
SUMMARY: PVAT surrounds blood vessels. PVAT and the 
adventitial layer of blood vessels are in direct contact with 
each other. Healthy PVAT secretes adipokines and regulates 
vascular function. Obesity is associated with changes in 
adipokine secretion and the resultant inflammation of PVAT. 
The dysregulation of adipokines changes the effect of PVAT 
on the vasculature. Changes in perivascular adipokines 
secretion in obesity appear to contribute to the development 
of obesity-mediated vascular disease.
LATAR BELAKANG: Obesitas terkait dengan resistensi insulin, dan penyakit kardiovaskular, tetapi mekanisme yang mendasari hubungan 
tersebut belum sepenuhnya dipahami. Disfungsi 
mikrovaskular memiliki peran penting pada patogenesis 
baik resistensi insulin maupun hipertensi pada obesitas.
ISI: Jaringan lemak perivaskular merupakan jaringan 
adiposa lokal yang terkumpul di sekeliling pembuluh darah. 
Jaringan lemak perivaskular ditemukan di seluruh tubuh 
dan terbukti memiliki pengaruh pada pembuluh darah. 
Pengaruh ini berubah sesuai dengan peningkatan adipositas. 
Sama seperti penyimpanan lemak yang lain, jaringan lemak 
perivaskular aktif secara metabolik, mensekresikan berbagai 
macam zat bioaktif yang disebut “adipokin”. Adipokin 
terdiri dari sitokin, kemokin, dan hormon yang bekerja 
secara parakrin, otokrin atau endokrin. Beberapa adipokin 
yang meningkat pada obesitas dapat mempengaruhi fungsi 
vaskular, termasuk fungsi endotel, stres oksidatif, kekakuan 
vaskular dan migrasi sel otot polos. Adipokin menstimulasi 
migrasi sel imun menuju ke dinding vaskular, yang 
berperan terhadap inflamasi pada aterosklerosis. Akhirnya, 
adipokin memodulasi kerja insulin pada pembuluh darah, 
yaitu menurunkan uptake glukosa otot yang dimediasi 
oleh insulin. Hal ini memicu perubahan signaling nitrit 
oksida, resistensi insulin, dan berpotensi memicu terjadinya 
aterosklerosis.
RINGKASAN: Jaringan lemak perivaskular mengelilingi 
pembuluh darah. Jaringan lemak perivaskular dan lapisan 
adventitial pada pembuluh darah berkomunikasi secara 
langsung satu sama lain. Jaringan lemak perivaskular yang 
sehat mensekresikan adipokin dan mengatur fungsi vaskular. 
Obesitas terkait dengan perubahan sekresi adipokin jaringan 
lemak perivaskular dan menyebabkan inflamasi. Disregulasi 
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The high prevalence of obesity throughout the world 
has increasingly focused on the association between 
body weight, cardiovascular risk factors and clinical 
cardiovascular disease.(1) Body fat distribution may be 
more strongly associated with obesity-related comorbidities 
and cardiovascular disease compared with generalized 
measures of adiposity, such as body mass index (BMI).(2-5)
 In humans and most animal models, the development 
of obesity leads not only to increased fat depots in classical 
adipose tissue locations but also to significant lipid deposits 
within and around other tissues and organs, a phenomenon 
known as ectopic fat storage. Ectopic fat, defined as the 
deposition of fat in non-classical locations including the 
heart, kidneys and blood vessels, may contribute to the 
development of cardiovascular disease by exerting a local 
toxic effect on adjacent structures.(6–8) One such ectopic 
fat depot is perivascular adipose tissue (PVAT), which 
is directly adherent to blood vessels. PVAT includes fat 
surrounding large arteries, as well as organ-specific fat 
depots in which adipose tissue surrounds the organ’s 
vasculature. Periaortic fat falls into the former category, 
whereas epicardial, pericardial and perirenal fat fall into the 
latter category.(9)
 PVAT has been shown to produce a variety of 
adipokines that contribute to regulation of vascular tone and 
local inflammation. Signaling from PVAT to the vasculature 
(“vasocrine” signaling) may not only cause vascular disease 
associated with obesity, but also reduce insulin-induced 
glucose disposal by reducing muscle perfusion. In recent 
years, evidence has emerged suggesting that this PVAT 
may hold one of the keys to effective future treatment or 
prevention of both insulin resistance and cardiovascular 
disease in obesity.(10)
the risk of development of metabolic and cardiovascular 
disease. This risk appears to stem from multiple abnormalities 
in adipose tissue function leading to a chronic inflammatory 
state and to dysregulation of the endocrine and paracrine 
actions of adipocyte-derived factors. These, in turn, disrupt 
vascular homeostasis by causing an imbalance between the 
nitric oxide (NO) pathway and the endothelin-1 system, 
with impaired insulin-stimulated endothelium-dependent 
vasodilation.(11)
 It is now well established that adipose tissue is not 
only involved in energy storage but also functions as an 
endocrine organ that secretes various bioactive substances.
(12,13) The dysregulated expression of these factors, 
caused by excess adiposity and adipocyte dysfunction, has 
been linked to the pathogenesis of various disease processes 
through altered immune responses.(14)
 The expression of adipokines can also vary depending 
on the site of an adipose tissue depot (Figure 1). The two 
most abundant depots are visceral and subcutaneous adipose 
tissues, which produce unique profiles of adipokines.
(15,16) In addition, adipocyte depots occur throughout the 
body in association with multiple organs, including the 
heart and kidneys. Adipocytes are also found in the bone 
marrow, lungs and the adventitia of major blood vessels. In 
some instances, it has been shown that high-calorie diets 
can promote the development of a pro-inflammatory state 
in these depots in a similar manner to that observed in 
subcutaneous and visceral adipose tissue.(17) Although the 
functional importance of many of these individual adipose 
depots is generally not known, recent evidence suggests 
that diet-induced changes in their adipokine secretion can 
influence the function of the associated tissue.(18)
 Accumulating evidence indicates that a state of 
chronic inflammation has a crucial role in the pathogenesis 
of obesity-related metabolic dysfunction.(19,20) Indeed, 
clinical and epidemiological studies have described a 
clear connection between the development of low-grade 
inflammatory responses and metabolic diseases, particularly 
in the context of obesity and type 2 diabetes. Excess adipose 
mass (as occurs in obese individuals) is associated with 
increased levels of the pro-inflammatory marker C-reactive 
adipokin merubah pengaruh jaringan lemak perivaskular 
terhadap pembuluh darah. Perubahan sekresi adipokin 
perivaskular pada obesitas berperan terhadap perkembangan 
obesitas menjadi penyakit vaskular.
KATA KUNCI: obesitas, jaringan lemak perivaskular, 
PVAT, penyakit kardiometabolik, adipokin
Adipose Tissue and Adipokine in Obesity
Obesity is an ongoing worldwide epidemic. Besides being 
a medical condition in itself, obesity dramatically increases 
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protein (CRP) in the blood.(21) Increased levels of CRP, 
and its inducer interleukin-6 (IL-6), are predictive of the 
development of type 2 diabetes in various populations.
(21,22)
 The adipose tissue provides vital information about 
its own mass and the whole body’s nutritional status to the 
brain and to insulin-sensitive organs and tissues through the 
synthesis and secretion of a number of adipokines such as 
leptin, adiponectin and resistin.(23,24) Leptin participates 
in the physiological regulation of appetite, by signalling the 
level of satiety to the brain.(25) Paradoxically, the majority 
of obese individuals have elevated circulating leptin levels, 
likely secondary to leptin resistance.(26) Furthermore, high 
leptin concentrations correlate with adverse cardiovascular 
outcomes in obese patients.(27)
 Adiponectin is an adipocyte-derived peptide that 
circulates in high concentrations in plasma(28) and whose 
actions include enhancement of insulin-mediated glucose 
uptake in skeletal muscle, suppression of hepatic glucose 
production and amelioration of insulin resistance.(29) 
Adiponectin’s concentrations, unlike most of the other 
adipokines, are inversely correlated with BMI(30) and 
visceral fat(31), and are reduced in patients with obesity and 
type 2 diabetes(32).
 Adiponectin is one of the few adipokines that 
possesses multiple salutary effects on insulin sensitivity 
and cardiovascular health. Clinical investigations have 
identified adiponectin deficiency (hypoadiponectinaemia) 
as an independent risk factor for cardiovascular disease 
(CVD). In animals, elevation of plasma adiponectin by either 
pharmacological or genetic approaches alleviates obesity-
induced endothelial dysfunction and hypertension, and also 
prevents atherosclerosis, myocardial infarction and diabetic 
cardiomyopathy. Adiponectin protects cardiovascular health 
through its vasodilator, anti-apoptotic, anti-inflammatory 
and anti-oxidative activities in both cardiac and vascular 
cells.(33)
 Resistin, an adipocyte-specific peptide in rodents, in 
humans is mainly produced by macrophages. It has been 
suggested that resistin may play a role in the development 
of insulin resistance and obesity(34) and that its levels may 
be increased in patients with type 1 and 2 diabetes(35). 
Evidence suggests that resistin is involved in pathological 
processes leading to CVD including inflammation, 
endothelial dysfunction, thrombosis, angiogenesis and 
smooth muscle cell dysfunction.(36)
 Resistin possibly binds to the membrane bound 
toll-like receptor 4, which then activates the intracellular 
signalling pathway. Resistin can activate the translocation 
of nuclear factor (NF)kB into the nucleus, which in turn, 
activates the transcription of pro-inflammatory cytokine 
genes, contributing to the proliferation of vascular smooth 
muscle cells (VSMCs) and endothelial dysfunction. 
Activation of NFkB can also be mediated by the resistin-
induced activation of phosphatidylinositol 3-kinase / Akt 
pathway. Resistin can also stimulate the production of 
pro-inflammatory cytokines through mitogen-activated 
protein kinase (MAPK) p38 and c-Jun N-terminal kinase. 
Resistin can cause oxidative stress, which is another factor 
for MAPK activation and endothelial NO synthase (eNOS) 
inhibition. Resistin increases the production of superoxide 
anions (O2
-), which inhibit eNOS gene expression and 
reduce bioavailability of NO. VSMCs proliferation and 
endothelial dysfunction including impaired vasorelaxation, 
Figure 1. Adipose tissue depots. (14) 
(Adapted with permission from Nature 
Publishing Group).
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enhanced thrombosis, hyperpermeability, angiogenesis 
and increased cell adhesion collectively contribute to the 
formation of atherosclerosis.(36)
 A group of adipokines, including adipocyte fatty 
acid binding protein (A-FABP) and lipocalin-2, possess 
specific lipid-binding activity and are up-regulated in 
obese human subjects and animal models. They act as lipid 
chaperones to promote lipotoxicity in endothelial cells 
and cause endothelial dysfunction under obese conditions. 
However, different small lipid-binding proteins modulate 
the development of vascular complications in distinctive 
manners, which are partly attributed to their specialized 
structural features and functionalities.(37)
 Several recent studies indicate that adipokines, such 
as leptin, resistin, IL-6 and tumor necrosis factor (TNF)a 
exert adverse effects on vasodilator function in animals with 
experimental obesity. These effects in part are mediated 
by elevated reactive oxygen species (ROS) production in 
the vascular wall. In obesity, during expansion of adipose 
tissue phenotypic changes of adipocytes occurs, which 
results in increased production of leptin, resistin, TNFa 
and IL-6. In addition to their systemic actions, these 
adipokines may locally induce production of O2
- in the 
adipose tissue arteriole. O2
-   interferes with the availability 
of NO and reduces dilator function of microvessels. Altered 
microvascular responsiveness may provoke hypoxia in 
the expanded adipose tissue, which via hypoxia inducible 
factor (HIF)1a would exaggerate pathological changes 
in adipokine production. Adipocytes may also enhance 
monocyte chemotactic protein 1 (MCP1) synthesis, which 
facilitates macrophage accumulation and activation, to 
maintain oxidative stress and adipose tissue inflammation.
(38)
 Obesity results in an imbalance between endothelium-
derived vasoactive factors favouring vasoconstriction, cell 
growth and inflammatory activation. Abnormal regulation 
of these factors due to endothelial cell dysfunction is both 
a consequence and a cause of vascular disease processes. 
Because of the similarities of the vascular pathomechanisms 
activated, obesity can be considered to cause accelerated, 
‘premature’ vascular aging.(39)
and organ function in two possible ways. First, the size 
of fat pads around key organs may increase substantially. 
This could modify organ function either by simple 
physical compression or because peri-organ fat cells may 
secrete various locally acting substances. Second, lipid 
accumulation can occur in non-adipose cells and may lead 
to cell dysfunction or cell death, a phenomenon known as 
lipotoxicity.(6,40,41)
 Throughout the body, most arteries and veins with a 
diameter greater than 100 μm are in contact with/surrounded 
by adipocytes. The term “perivascular adipose tissue” refers 
to adipose tissue around vessels, irrespective of location. 
Known locations of PVAT include the coronaries (epicardial 
adipose tissue)(42), aorta (periaortic adipose tissue)(43), and 
the microvascular beds of the mesentery(44), muscle(45), 
kidney(6), and adipose tissue(46).
 PVAT consists of adipocytes, fibroblasts, stem 
cells(47), mast cells(48,49), and nerves(48). PVAT is 
initially formed in the embryological phase and remains in 
place throughout life; in times of nutrient abundance and 
obesity, PVAT expands and undergoes an inflammatory 
transformation. The volume of PVAT is associated with 
the quantity of intra-abdominal adipose tissue(50,51). 
Accumulating evidence suggests that the products of PVAT 
(ie, adipokines) contribute to regulation of vascular function. 
In this regard, both protective physiologic and pathologic 
properties of PVAT have been proposed(10).
Ectopic fat storage in the heart
Most animal models of obesity as well as obese humans 
show an increased cardiac mass. In the rabbit model of 
obesity, a 50% gain in body weight led to an increase in dry 
weight of the right and left ventricles by about 70 and 50%, 
respectively, and to an increase in protein content by about 
50% in both right and left ventricles.(52) Overall, those 
changes led to significant alterations in cardiac function. To 
what extent the cardiac changes observed in obesity are due 
to ectopic fat storage is not clear. In fact, the combination of 
a mild increase in blood pressure, increase in cardiac output, 
increase in the heart rate-pressure product, and ectopic fat 
storage within and around the heart, could have additive 
effects resulting in the frequent observation of systolic and 
diastolic dysfunctions in obesity, which in the long term 
promote heart failure.(6)
Ectopic fat storage around blood vessels
Nearly, all blood vessels in the body are surrounded 
by variable amounts of adventitial fat. Traditionally, 
perivascular fat has been assumed to serve as structural 
support for the vasculature. However, perivascular fat 
In humans and most animal models, the development of 
obesity leads not only to increased fat depots in classical 
adipose tissue locations but also to significant lipid deposits 
within and around other tissues and organs (ectopic fat 
storage). With fat gain, lipid deposition can impair tissue 
Ectopic Fat Storage inHeart and Blood Veseel
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has been shown to modulate vascular responsiveness to 
vasoactive agents in  studies of the aorta(53,54) and of 
the mesenteric vessels(44). Interestingly, diet-induced fat 
deposition in experimental models of obesity is not limited 
to the subcutaneous fat and to the classical visceral depots 
in tight connection with mediastinic and abdominal organs, 
but also occurs along the major blood vessels.(55) The 
pathophysiological consequences of increased perivascular 
fat in obesity could simply be mechanical. As more adipose 
tissue wraps around blood vessels, it is conceivable that the 
large amounts of perivascular fat could contribute to the 
increased vascular stiffness often observed in obese subjects. 
Excess body weight is associated with higher aortic stiffness 
as determined by magnetic resonance imaging techniques 
(56) or by aortic pulse wave velocity measurements.(57) 
What is worrisome is that the strength of this association 
can be seen in very young adults.(57) In fact, noninvasive 
measurements of the carotid artery by ultrasound imaging 
in severely obese children revealed a significantly greater 
carotid stiffness.(58) In addition, perivascular fat could 
act as a secretory organ to influence the neighboring blood 
vessels. This function of perivascular fat is very intriguing 
since studies in isolated blood vessels have shown that the 
contractile response of rat aortic rings to angiotensin II, 
serotonin and phenylephrine was significantly attenuated in 
the presence of periadventitial fat.(54)
Ectopic fat storage in the kidney
The development of obesity-induced hypertension in 
dogs(59) and rabbits(60) is associated with significant 
sodium retention in spite of a marked increase in GFR. 
Analysis of renal artery pressure–sodium excretion 
relationship in obese dogs fed an HFD for 5–6 weeks reveals 
a shift to the right as well as a decrease of the slope of the 
pressure–natriuresis curve.(61) Many mechanisms(62) have 
been suggested to explain this abnormal sodium handling, 
including increased renal nerve sympathetic activity, 
activation of the renin–angiotensin–aldosterone system, 
as well as direct sodium-retaining effects of insulin. In 
addition, there is evidence that weight gain is associated 
with abnormal physical forces within the kidney that could 
promote sodium retention.(63) The mechanisms by which 
weight-gain leads to abnormal intrarenal physical forces are 
complex, but could be related to the marked structural renal 
changes observed in animal models of diet-induced obesity 
(dogs, rabbits). Accumulation of fat in the renal sinus (sinus 
lipomatosis) may favor compression of the renal inner 
medulla and of hilum structures.(6) Taken together, ectopic 
fat storage in key target-organs of cardiovascular control 
may impair their functions, contributing to the increased 
prevalence of cardiovascular diseases in obese subjects.
Fifty years ago, the vision of vascular control was rather 
simple: besides local metabolites directly governing the 
opening of arterioles in function of the needs of the tissues, 
daily vascular regulation was pretty much the affair of the 
omnipotent sympathetic adrenergic nervous system. A first 
glimpse of the importance of local modulation of the control 
of vascular tone came with the realization that a number of 
factors could impinge on the adrenergic nerve endings and 
reduce or augment the amount of noradrenaline released per 
nerve impulse reaching the adrenergic varicosities.(64)
 A further fundamental breakthrough was the discovery 
that endothelial cells could initiate relaxations(65) or 
contractions(66) of the underlying vascular smooth muscle, 
permitting the concept of endothelium-dependent control of 
vascular tone.(67,68) Thirty years later we know a lot about 
nitric oxide, endothelium-dependent hyperpolarization, 
endothelins and endothelium-derived vasoconstrictor 
prostaglandins but we still do not understand all the 
complexities of endothelial control.(69-75)
 Both in the animal and in humans, obesity results 
in progressive endothelial dysfunction, not only in large 
arteries, but also at the level of the microcirculation, 
which then helps us to understand why it is a major risk 
factor for cardiovascular disease.(11,28,38,39) Obesity 
has detrimental effects on the microcirculation. Functional 
changes in microvascular responsiveness may increase 
the risk of developing cardiovascular complications in 
obese patients. Emerging evidence indicates that selective 
therapeutic targeting of the microvessels may prevent life-
threatening obesity-related vascular complications, such 
as ischaemic heart disease, heart failure and hypertension. 
It is also plausible that alterations in adipose tissue 
microcirculation contribute to the development of obesity.
(38)
 Although most of the systemic arteries except the 
cerebral vasculature are surrounded by PVAT, the functional 
role of PVAT other than as a structural support of the blood 
vessel has long been neglected. Recent studies, however, 
indicate a crucial role of PVAT not only in the regulation 
of blood vessel function but also in its structure.(76) PVAT 
secretes more pro-inflammatory cytokines such as IL-6, IL-8 
and MCP-1 than subcutaneous adipose tissue.(17) Because 
PVAT encroaches into the adventitia without an anatomical 
barrier, it is suggested that humoral factors secreted by PVAT 
easily access the blood vessel wall, indicating that PVAT 
functions as a paracrine organ that transduces metabolic 
signals to blood vessels.
 Today’s paradigm holds that the vascular wall consists 
PVAT as Regulator of Vascular Function
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vessel contraction.
 Lohn et al.  described in 2002 the so-called 
“adventitium-derived relaxing factor” (ADRF), which 
was shown to be produced by isolated adipocytes and 
diminished the contractile response of intact aortic rings 
to serotonin, angiotensin II, or phenylephrine.(54) They 
suggested that PVAT release a transferable ADRF that 
acts by tyrosine kinase-dependent activation of potassium 
channels in vascular smooth muscle cells. The molecular 
nature of ADRF is still unknown; however, its presence 
has been confirmed in small mesenteric arteries.(88) ADRF 
acts independently of leptin receptors; however, leptin 
itself was also able to diminish angiotensin II-induced 
vasoconstriction by leptin receptor-mediated inhibition of 
intracellular calcium increase in smooth muscle cells of the 
rat aorta.(89)
 Result from study by Fesus et al., demonstrated that 
the anti-contractile effects of perivascular fat occur through 
access of ADRF from outside the vessel (‘outside control’).
(86) The possible contribution by perivascular adipocytes to 
the regulation of vascular tone and to vascular remodeling 
appears to be especially important because of the current 
obesity epidemic that has resulted in increased numbers of 
diabetic and hypertensive patients. If perivascular adipocytes 
react like adipocytes in other depots, a dysregulation of the 
secretion of vasoactive and proinflammatory molecules can 
then be expected.(90)
 Recent studies explored the possibility that ADRF 
might be a volatile, gaseous mediator that disappears into 
the atmosphere during purification.(91) Previously, studies 
demonstrated that NO is not ADRF.(44,54) The possibility 
that ADRF might be another biological active gaseous 
mediator, such as H2S or carbon monoxide (CO). H2S is 
a newly discovered physiologic vasorelaxant generated 
by cystathionine gamma lyase (CSE).(92) This enzyme is 
expressed in PVAT and endogenously generates H2S.(93)
 Fang et al. obtained similar results with CSE inhibitors 
in the rat aorta. In an elegant series of experiments, they 
measured endogenous H2S production in the aorta and found 
that serotonin, phenylephrine and angiotensin II increase 
H2S release from PVAT. Release of H2S is decreased 
with aging of rats and can be blocked by CSE inhibitors.
(94) Nonetheless, the data indicate that H2S represents a 
candidate or modulator of ADRF.
 ADRF is released by visceral periadventitial 
adipocytes and primarily produces endothelium-
independent vasorelaxation by opening Kv channels 
Figure 2. Interaction of PVAT with vascular endothelium, smooth 
muscle, and immune cells and the mediators involved.(10) (Adapted 
with permission from Springer).
of 3 layers: the tunicae intima, media, and adventitia. 
Chalkadov et al. suggest that PVAT may indeed be 
considered the fourth, outermost vascular layer, that is, 
tunica adiposa. Because there is a lack of any fascia-like 
structure between the adventitia and the PVAT.(77,78) PVAT 
is a producer of a large number of bioactive molecules such 
as adipokines(77-80), which, in a paracrine way, may exert 
proinflammatory and smooth muscle cell growth/migration 
promoting, in fact, atherogenic effects(79) and PVAT 
releases vasorelaxing factor(s)(81), which may benefit the 
vascular biology, hence, a question whether PVAT is an 
enemy or a friend of the artery may emerge(82).
 Recent in vitro and in vivo evidence identifies adipose 
tissue as a critical endocrine organ that secretes a variety 
of bioactive signalling molecules into the circulation. 
These molecules include vascular endothelial growth factor 
(VEGF), IL-6, IL-1, TNFa, leptin, adiponectin (ACRP30), 
resistin, omentin, acylation stimulation protein (ASP), 
apelin, adipsin, agouti, insulin-like growth factor (IGF-1), 
angiotensinogen, plasminogen activator protein (PAI-1), 
ROS and sex steroids.(83-85) These substances can play an 
autocrine role in the regulation of adipocyte metabolism. 
Upon secretion into the bloodstream, they can also play an 
endocrine role in the regulation of other cellular processes, 
including vascular function and peripheral resistance.
 Although adiponectin has been reported to relax 
aortic and mesenteric artery by opening voltage-dependent 
K+ (Kv) channels(46,86), adiponectin is not an adipocyte-
derived relaxing factor because the anti-contractile effects 
of PVAT are preserved in adiponectin-deficient mice(86). 
Intriguingly, PVAT enhances the arterial contractile response 
to perivascular nerve stimulation through NADPH oxidase-
mediated superoxide production.(87) Therefore, PVAT from 
normal animals has a dual role in the regulation of blood 
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of the anti-contractile effect of healthy PVAT. This makes 
sense because accumulation of lipid and infiltration of 
inflammatory cells into the PVAT may cause hypoxia, and 
hypoxia is known to induce oxidative stress and cytokine 
production.(96)
 The PVAT of obese patients may cause structural 
remodeling of the blood vessel. The thickness including 
adventitia and PVAT in the carotid artery is increased in 
patients with diabetes and dyslipidemia, and the thickness is 
correlated with intima-media thickness of the carotid artery.
(97)
in the plasma membrane of smooth muscle cells.(95) 
Kv7 family of potassium (KCNQ) channels exhibit a 
large hyperpolarisation reserve and are enabled to fulfil 
physiological vasodilatory functions in the presence of 
perivascular fat, i.e. in response to ADRF. Moreover, since 
ADRF is released from perivascular adipocytes, KCNQ 
channels seem to play a unique role for vasodilatory signals 
from outside the vessel (‘outside control’). KCNQ channels 
are not targeted by endothelium- derived relaxing factors 
(EDRF) (‘inside control’), including NO, prostaglandin I2 
(prostacyclin) and endothelium-derived hyperpolarizing 
factor (EDHF).(95) KCNQ channels are also not targeted 
by other perivascular candidates, such as H2O2, superoxide 
and Angiotensin 1-7. The data support the novel concept 
that ADRF H2S is the physiological activator of KCNQ 
channels, at least in part, in visceral arteries.
 The dilator effect of PVAT in patients with obesity 
and metabolic syndrome is lost.(46) The obese phenotype 
of PVAT could be mimicked by addition of inflammatory 
cytokines such as TNFα or IL-6 to healthy PVAT, confirming 
a pivotal role of adipokines in blood vessel dysfunction. 
This study also showed that hypoxia resulted in the loss 
Figure 3. Potential mechanisms via which perivascular adipocytes, vascular smooth muscle cells and endothelial cells interact.(98) 
(Adapted with permission from Wiley and Sons, Inc.).
PVAT and Cardiometabolic Diseases
Atherosclerosis is traditionally viewed as a disease of the 
vascular intima, following a paradigm of endothelial cell 
dysfunction, inflammatory cell recruitment, and foam 
cell formation.(98-102) More recently, dysfunction of 
medial smooth muscle cells and adventitial cells has also 
been demonstrated to play a role in the pathogenesis of 
atherosclerosis.(103,104) Recent evidence indicates that the 
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fat is defined anatomically as the fat located between the 
myocardium and visceral pericardium. Pericardial fat has 
been defined by MDCT in two ways. The first definition, 
used by the FHS, includes any fat located within the 
pericardial sac. The second definition of pericardial fat, used 
by the Multi-Ethnic Study of Atherosclerosis (MESA) and 
the Jackson Heart Study (JHS), includes both epicardial fat 
and paracardial fat. Paracardial fat includes fat covering the 
parietal pericardium.(9)
 Current research on perivascular fat opens a new field 
in vascular biology. Both the intimal endothelium and the 
adventitial fat regulate contraction and growth of medial 
VSMCs.(114) The crosstalk between cells in the blood 
vessel wall is vital for normal vascular function. Imbalance 
of PVAT-derived factors may play a role in proliferative 
vascular diseases such as atherosclerosis, restenosis and 
hypertension. To identify key factors altered in distinct 
sites of PVAT and involved in stimulation of proliferation 
may help to develop new therapies for the prevention and 
treatment of vascular disease.
 PVAT is significantly correlated with most 
cardiometabolic risk factors and coronary artery calcification 
(CAC) in the JHS cohort. The results suggest that PVAT is 
an important VAT depot that may exert a local effect on the 
coronary vasculature.(115) Preservation of PVAT may be as 
important as preservation of endothelium for a successful 
vascular intervention.
 Yudkin et al. originally postulated that PVAT might 
hold the key to linking obesity with the development of 
metabolic syndrome and diabetes as a result of an adverse 
influence upon the vasculature.(45) In health, PVAT could 
produce adipokines that profoundly influence metabolism 
and the control of local vascular tone via vasocrine actions. 
It was suggested that the loss of such substances would 
result in a change in vascular function and development of 
insulin resistance.(98)
 As mentioned above, vascular function and especially 
microvascular blood volume in muscle are related to insulin 
sensitivity. Because obesity is associated with insulin 
resistance, reduction of microvascular blood volume, and 
altered properties of PVAT, we have proposed that PVAT 
causes microvascular dysfunction and insulin resistance in 
obesity.(45) Although there are, at present, no studies that 
prospectively link PVAT to diabetes, a number of studies 
provide indirect evidence for this hypothesis.(10)
 First, several studies suggest that ectopic adipose 
tissue, especially within muscles, strongly relates to insulin 
sensitivity. The amount of PVAT surrounding the brachial 
artery(51) and adipose tissue between muscle (intermuscular 
adipose tissue (IMAT))(116) are inversely related to insulin 
sensitivity. Even though IMAT accounts for only 3% of total 
periadventitial adipose depot is a functional component of 
the vasculature, exerting paracrine influences on blood vessel 
contractility.(44,54) By virtue of their unique functional and 
biochemical properties, perivascular adipocytes may play 
a primary role in establishing adventitial inflammation in 
atherosclerosis.(17)
 Obesity is associated with inflammation of adipose 
tissue (24,105) Much of the evidence demonstrating the 
association of obesity with adipose inflammation comes 
from the study of visceral adipose tissue (VAT).(24) 
However, growing evidence supports a similar process in 
PVAT.(17,24,42,106) IL-1β, IL-6, MCP-1 and TNFα were 
shown to be higher in obese subjects undergoing bypass 
surgery in epicardial as opposed to subcutaneous fat.(42). 
In related studies, in vitro differentiated human perivascular 
adipocytes demonstrated increased levels of IL-8, IL-6 and 
MCP-1 compared with subcutaneous adipose tissue.(17)
 The recognition that perivascular adipose inflammation 
potentially contributes to atherosclerosis has led to an 
‘outside-in’ theory of vascular inflammation. Vascular 
inflammation was already believed to follow an ‘inside-
out’ process in which intimal injury leads to expression 
of vascular adhesion molecules, release of inflammatory 
signals and subsequent homing of blood-borne immune cells 
to the endothelium.(107) This intimal inflammation then 
spreads into the media and adventitia.(108) The ‘outside-
in’ theory postulates that inflammation begins in adipose 
tissue and then spreads inward to the vasculature.(104) 
This is supported by the lack of a fascial plane between the 
adventitia and surrounding adipose tissue, as well as the 
extension of the vasa vasorum into PVAT.(82) Consistent 
with this, immunostaining of atherosclerotic human aortas 
has shown the presence of inflammatory cells at the junction 
of PVAT and the vascular adventitia.(9,106)
 The use of imaging modalities to quantitatively assess 
the amount of PVAT in specific perivascular fat depots has 
been fundamental to the epidemiological study of obesity 
and vascular disease. To date, most imaging of PVAT has 
focused on pericardial fat, which can be measured by 
ultrasound, multidetector computed tomography (MDCT) 
and MRI.(7,109-111). More recently, a reliable method for 
the assessment of periaortic fat volume has been developed.
(112)
 The associations of epicardial and pericardial fat with 
metabolic risk factors, indices of myocardial structure and 
function and clinical vascular disease have been assessed in 
epidemiological studies. These studies have used multiple 
imaging modalities, and the terminology differs depending 
on the technique used. Echocardiographic studies generally 
use the term ‘epicardial fat’, whereas MDCT studies 
generally use the term ‘pericardial fat’.(7,113) Epicardial 
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thigh adipose tissue, it has the strongest correlation with 
insulin sensitivity in obese subjects and subjects with type 2 
diabetes mellitus.
 Second, vascular function, especially muscle 
perfusion, contributes to regulation of insulin-mediated 
glucose disposal. Increased amounts of adipose tissue, as 
observed in obese subjects and rats, are accompanied by 
impairment of muscle perfusion. Impairment of muscle 
perfusion has been estimated to account for 30% to 50% of 
insulin resistance.(117)
 Third, accumulation of PVAT around the arterioles 
that regulate muscle perfusion. Aside from intermuscular 
adipose tissue and PVAT around the femoral artery, we have 
found that PVAT exists within muscles (ie, intramuscular 
PVAT (mPVAT)). This location is especially relevant given 
the increasing evidence for regulation of muscle insulin 
sensitivity by microvascular perfusion in muscle.(117,118) 
By regulating endothelium-dependent vasodilatation, 
insulin-mediated vasoreactivity, and muscle perfusion, 
mPVAT may control muscle glucose uptake and, thus, 
determine risk of future type 2 diabetes.(10)
 The mechanisms controlling the quantity of PVAT and 
adipokine secretion from PVAT remain to be determined. 
Because PVAT is related to insulin resistance, controls 
vascular function, and is located within insulin target 
tissues, it may well contribute to the pathogenesis of type 2 
diabetes as well as cardiovascular disease.(10)
 In summary, PVAT is in close connection with the 
media of blood vessels, separated from it only by a very 
thin adventitial layer. The mass of perivascular fat increases 
in obesity and it is postulated that a paracrine secretion of 
various growth-stimulating and proinflammatory agents 
could contribute to the pathogenesis of cardiovascular 
diseases (6). PVAT is increasingly recognized as a 
widespread, relevant tissue in vascular biology and 
important determinant of cardiometabolic complications of 
obesity.
Adipose tissue is an active endocrine and paracrine organ 
that may influence the development of atherosclerosis 
and vascular disease. In the setting of obesity, adipose 
tissue produces a variety of inflammatory cytokines (or 
adipokines) that are known to modulate key mechanisms 
of atherogenesis. In particular, adipose tissue located on the 
surface of the heart surrounding large coronary arteries (i.e. 
epicardial PVAT) has been implicated in the pathogenesis 
of coronary artery disease. The organism’s perivascular 
adipocytes act as an integrated organ responsible for 
Figure 4. Schematic diagram for perivascular fat 
dysfunction and vascular disease. (114) (Adapted with 
permission from Wiley and Sons, Inc.).
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paracrine and vasocrine signalling, which in turn contributes 
to skeletal muscle insulin resistance.
 The pathophysiology of PVAT in obesity and its 
influence on oxidative stress, inflammation, insulin 
resistance, endothelial dysfunction and vascular reactivity 
is well established. In addition, the contribution of specific 
epicardial perivascular adipose-derived adipokines (e.g. 
leptin, adiponectin) to the initiation and expansion of 
coronary disease is also evidenced. Future investigative 
with an emphasis on indentifying novel therapeutic targets 
and disease markers within PVAT are promising.
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